Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.

Categoría Estudio primario
RevistaAIDS (London, England)
Año 2000
Cargando información sobre las referencias
Reports the results of a prospective, randomized, open trial, in which the virologic and immunologic efficacy, as well as the impact of quality of life and morpho-metabolic lipodystrophic parameters were assessed in HIV-positive Ss switched to a nevirapine (NVP)-based regimen after being on long-term sustained virus suppression under a protease inhibitor (PI)- containing combination. 138 Ss were randomly assigned to either replace the PI by NVP or continue on the same treatment. Plasma viral load, CD4 count, lipid profile and body-shape features were all assessed at the time of randomization and at 3 and 6 mo follow-up and a quality of life (QOL) questionnaire was also performed in each control. In an intent-to-treat analysis, a rebound in viral load occurred in 8% and 4% of Ss at follow-up after simplification. Overall most patients who switched to NVP treatment described a global improvement in their QOL. The replacement of PI by NVP in triple combinations after long-lasting successful response to PI containing regimens appears to be safe and convenient. Improvements in body-shape lipodystrophic abnormalities and QOL can be recognized, although reversion of metabolic disturbances might require a longer follow-up. (PsycInfo Database Record (c) 2021 APA, all rights reserved)
Epistemonikos ID: 03af75e84d15762eb02162eb4f5d41c515121afb
First added on: May 06, 2015